News | October 10, 2011

Zilver PTX DES Could Greatly Reduce Need for Leg Amputations, Bypass Surgery


October 5, 2009 – In a breakthrough development that could dramatically reduce the number of leg amputations and painful bypass graft surgeries performed annually on European patients, a first-of-its kind drug-eluting stent for a widespread form of peripheral arterial disease (PAD) is now available to physicians throughout the European Union.

Cook Medical said its new CE-marked Zilver PTX Drug-Eluting Peripheral Stent is widely expected to improve the standard of care for many patients with serious blockages in the superficial femoral artery (SFA) by creating a highly effective, completely new treatment option. In the largest clinical trial of its kind ever conducted, the Zilver PTX stent was shown to effectively bridge the gap between the patient results achieved using open surgical bypass graft procedure, which is typically more painful and requires a longer hospital stay for the patient, and the less traumatic, but typically less effective, earlier minimally invasive treatment options for PAD such as balloon angioplasty and bare metal stenting[1].

Cook’s device was introduced commercially to European physicians at the annual CIRSE meeting, Sept. 19-23 in Lisbon. The launch includes several important developments, including the introduction of a new Web site, www.cookmedical.com/zilverptx, with clinical and practical information on the device for patients and physicians in English and major European language languages.

Cook also has initiated a first-of-its-kind open clinical database on SFA treatments. The SFA Open-Registry provides physicians with an opportunity to exchange ongoing, real world treatment results. Utilizing an intuitive Web interface, clinicians may track their patients, view the medical community’s trends in treating PAD and determine the most effective treatment options. Transparency will be a central objective of the SFA Open-Registry, with results for all treatment types available to participating physicians.

As part of its ongoing corporate mission to help reduce global healthcare delivery costs, Cook has adopted an “affordable innovation” strategy aimed at reducing any potential financial or reimbursement barriers to its widespread adoption as the standard of care for PAD in the SFA.

The first DES approved for treating PAD in the superficial femoral artery (SFA), the difficult-to-treat, largest blood vessel in the leg, the Zilver PTX stent first expands and holds open the artery to restore blood flow. The device then delivers the drug paclitaxel to the cells in the vessel wall to reduce the risk of new blockages forming. In a major advance over previous drug-eluting technologies, the Zilver PTX achieves targeted drug delivery without using a polymer to adhere the drug to the stent body. This eliminates the potential patient risks associated with polymer-coated devices, including clot formation and inflammation.

Cook licenses the rights to use paclitaxel on peripheral stents and other noncoronary medical devices from Angiotech Pharmaceuticals Inc. of Vancouver, British Columbia, Canada. In the United States, the Zilver PTX Drug-Eluting Stent is an investigational device not available for sale at this time.

For more information: www.cookmedical.com

Related Content

The Abbott Absorb Bioresorbable Vascular Scaffold (BVS) bioabsorbable stent.

The Abbott Absorb Bioresorbable Vascular Scaffold (BVS).

Feature | Stents Drug Eluting| January 17, 2018 | Dave Fornell
There was no shortage of interest in bioresorbable stent technologies at the many sessions offered on this topic or b
Cordis and Medinol Announce FDA Approval of EluNIR Drug-Eluting Stent System
Technology | Stents Drug Eluting| December 13, 2017
Cordis, a Cardinal Health company, and Medinol recently announced U.S. Food and Drug Administration (FDA) approval of...
The Xience Sierra stent.
Technology | Stents Drug Eluting| November 09, 2017
November 9, 2017 — Abbott received European CE mark for Xience Sierra, the newest generation of the company's Xience
Synergy Stent With Shorter DAPT Superior to Bare-Metal Stent in Elderly Patients
News | Stents Drug Eluting| November 06, 2017
November 6, 2017 — Elderly patients undergoing...
Biotronik Orsiro DES Shows Low Five-Year Event Rates
News | Stents Drug Eluting| November 03, 2017
November 3, 2017 — Biotronik's Orsiro...
Three-Month DAPT Non-Inferior for ACS Patients Treated With Combo Dual Therapy Stent

Image courtesy of OrbusNeich

News | Stents Drug Eluting| November 01, 2017
OrbusNeich reported results from the REDUCE trial in the Late-Breaking Clinical Trial session at the 29th annual...
News | Stents Drug Eluting| October 25, 2017
Elixir Medical Corp. announced it will unveil a new metallic drug-eluting stent (DES) platform at this year’s...
Biotronik's Orsiro Drug-Eluting Stent Outperforms Xience in BIOFLOW-V Trial
News | Stents Drug Eluting| September 01, 2017
September 1, 2017 — Biotronik recently announced data from the BIOFLOW-V randomized trial comparing Orsiro and Xience
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Overlay Init